No Data
No Data
Insiders of Dianthus Therapeutics Getting Good Value On Their US$2.05m Investment
Insiders who bought Dianthus Therapeutics, Inc. (NASDAQ:DNTH) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$177m as a result of the stock's 29%
Express News | Dianthus Therapeutics Shares Are Trading Higher After the Company Announced FDA. Clearance of Its Phase 2 Investigational New Drug Application for the MoMeNtum Trial of DNTH103 in Patients With Multifocal Motor Neuropathy
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $45
LifeSci Capital analyst Rami Katkhuda maintains $Dianthus Therapeutics(DNTH.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of
Dianthus Wins FDA Nod to Start Mid-stage Trial for Lead Asset
Express News | Dianthus Therapeutics Inc: Top-Line Results From Phase 2 Momentum Trial in Multifocal Motor Neuropathy Anticipated in 2H 2026
Express News | Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of Dnth103 in Multifocal Motor Neuropathy (Mmn)